Filed on behalf of: Roxane Laboratories, Inc.

Entered: November 10, 2016

#### UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

#### BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

## ROXANE LABORATORIES, INC. Petitioner

v.

NOVARTIS AG
Patent Owner

\_\_\_\_\_

Case IPR2016-01102 U.S. Patent No. 5,665,772

Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and ROBERT A. POLLOCK, *Administrative Patent Judges*.

PETITIONER'S REQUEST FOR REHEARING OF THE BOARD'S DECISION DENYING JOINDER



### **TABLE OF CONTENTS**

Table	of A	uthorities	ii
I.	Legal Standard		
II.	Argument		3
	A.	The Board Did Not Explain Why Roxane Should Be Prejudiced By Deficiencies In The Par I IPR Petition	3
	B.	The Board Improperly Denied Roxane's Joinder Motion Based On Scheduling Complications Beyond Roxane's Control	4
	C.	The Board Erred In Failing To Take Into Account The Public Interest	6
III.	Conclusion		7



## **TABLE OF AUTHORITIES**

	Page(s)
Cases	
Consol. Bearings Co. v. United States, 348 F.3d 997 (Fed. Cir. 2003)	3
Cuozzo Speed Techs. v. Lee, 136 S.Ct. 2131 (2016)	6
In re Gartside, 203 F.3d 1305 (Fed. Cir. 2000)	3
James V. Hurson Assoc., Inc. v. Glickman, 229 F.3d 277 (D.C. Cir. 2000)	6, 7
Statutes	
35 U.S.C. § 316(a)(12)	4
35 U.S.C. § 316(a)(11)	5
Other Authorities	
37 C.F.R. §42.71(c)	2
37 C.F.R. §42.71(d)	2
37 C.F.R. § 42.100(c)	5
37 C.F.R. § 42.122 (b)	4
77 Fed. Reg. 48680	4, 5
Legislative History	
157 Cong. Rec. S1376	4, 5, 6



Petitioner Roxane Laboratories, Inc. ("Roxane") respectfully requests rehearing of the Board's Decision denying joinder, Paper 17 (Oct. 27, 2016) ("Dec.").

Roxane timely filed an IPR petition requesting review of claims 1-3 and 7-10 of the '772 patent (the "Roxane Petition") and a Motion for Joinder with Par Pharmaceutical, Inc.'s ("Par's") IPR2015-00084 (the "Par I IPR"), instituted on claims 1-3 and 8-10 of the '772 patent. The Board granted Roxane's Motion for Joinder with respect to claims 1-3 and 8-10, but denied it with respect to claim 7. The Board also denied a second IPR petition submitted by Par, directed to claim 7 of the '772 patent (IPR2016-01059; the "Par II IPR").

Roxane is aware that Par is concurrently filing a Request for Rehearing of the Board's Decision denying joinder in the Par II IPR. The subject of Par's Request for Rehearing is the same as that of the present Request for Rehearing. If Par's Request for Rehearing is granted, Roxane's Request for Rehearing likewise should be granted.

The Board agreed that the Roxane Petition established that claim 7 of the '772 patent is likely obvious. Dec. at 12. The only difference between claim 7 and claim 1 is that claim 7 recites a composition comprising a therapeutically effective amount of the compound of claim 1 and an acceptable carrier, without any further specificity. Nevertheless, the Board did not institute review. Accordingly, if the



Case IPR2016-01102 U.S. Patent No. 5,665,772

Board finds that claims 1-3 and 8-10 are unpatentable, claim 7 will block the public from using an obvious compound, for its obvious methods of use.

The Board identified two reasons for denying Roxane's joinder motion as to claim 7. Dec. at 15. First, according to the Board, Par's inadvertent omission of claim 7 in the Par I IPR petition is not a "sufficient justification for the grant of joinder." *Id.* at 15. Second, according to the Board, the joinder of claim 7 would "unduly complicate" and cause "undue delays" in the Par I IPR proceeding, to which Roxane has been joined. *Id.* at 17.

In denying joinder, the Board misapprehended or overlooked at least the following matters. First, the Board did not explain why Roxane should be prejudiced by Par's failure to include claim 7 in the Par I IPR. Second, the Board abused its discretion when it found that joining claim 7 would cause undue delays and unduly complicate the Par I IPR. Third, the Board failed to adequately account for the public interest.

## I. Legal Standard

A party seeking rehearing must identify the matters that the Board misapprehended or overlooked. 37 C.F.R. §42.71(d). The Board reviews its decision for an abuse of discretion, 37 C.F.R. §42.71(c), which occurs when the "decision represents an unreasonable judgment in weighing relevant factors" or "the agency offers insufficient reasons for treating similar situations differently."



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

